Guven, D. C. Et Al. 2022. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16 .

Guven, D. C., Sayegh, N., Tripathi, N., Erman, M., Agarwal, N., & Swami, U., (2022). Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16.

Guven, DENİZ Et Al. "Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.," JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022

Guven, DENİZ C. Et Al. "Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022

Guven, D. C. Et Al. (2022) . "Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16.

@article{article, author={DENİZ CAN GÜVEN Et Al. }, title={Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2022}